Find Research Outputs

Search in all content

Filters for Research Outputs

Search concepts
Selected filters

Publication Year

  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011

Author

  • Richard Kefford

18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma

Carlino, M. S., Saunders, C. A. B., Haydu, L. E., Menzies, A. M., Martin Curtis, C., Lebowitz, P. F., Kefford, R. F. & Long, G. V., Jan 2013, In : European Journal of Cancer. 49, 2, p. 395-402 8 p.

Research output: Contribution to journalArticle

25 Citations (Scopus)

Absence of distinguishing senescence traits in human melanocytic nevi

Tran, S. L., Haferkamp, S., Scurr, L. L., Gowrishankar, K., Becker, T. M., Desilva, C., Thompson, J. F., Scolyer, R. A., Kefford, R. F. & Rizos, H., Sep 2012, In : Journal of Investigative Dermatology. 132, 9, p. 2226-2234 9 p.

Research output: Contribution to journalArticle

30 Citations (Scopus)

A case of diffuse melanosis cutis with positive BRAF mutation status and treatment with targeted therapies

Minocha, R., Uribe, P., Kefford, R. & Penas, P. F., May 2014, In : Australasian Journal of Dermatology. 55, Supplement s1, p. 41-41 1 p.

Research output: Contribution to journalMeeting abstract

Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy

Uribe, P., Anforth, R. M., Kefford, R. F. & Fernandez-Peñas, P., 1 Oct 2014, In : Melanoma Research. 24, 5, p. 501-503 3 p.

Research output: Contribution to journalArticle

6 Citations (Scopus)

Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib

Anforth, R., Liu, M., Nguyen, B., Uribe, P., Kefford, R., Clements, A., Long, G. V. & Fernandez-Peñas, P., 1 Nov 2014, In : Australasian Journal of Dermatology. 55, 4, p. 250-254 5 p.

Research output: Contribution to journalArticle

28 Citations (Scopus)

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

Johnson, D. B., Menzies, A. M., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Rizos, H., Sucker, A., Scolyer, R. A., Gutzmer, R., Gogas, H., Kefford, R. F., Thompson, J. F., Becker, J. C., Berking, C., Egberts, F., Loquai, C., Goldinger, S. M., Pupo, G. M., Hugo, W. & 7 others, Kong, X., Garraway, L. A., Sosman, J. A., Ribas, A., Lo, R. S., Long, G. V. & Schadendorf, D., 1 Dec 2015, In : European Journal of Cancer. 51, 18, p. 2792-2799 8 p.

Research output: Contribution to journalArticle

124 Citations (Scopus)

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., Kelley, M. C., Kefford, R. F., Chmielowski, B., Glaspy, J. A., Sosman, J. A., Van Baren, N., Long, G. V., Ribas, A. & Lo, R. S., Jan 2014, In : Cancer Discovery. 4, 1, p. 80-93 14 p.

Research output: Contribution to journalArticle

545 Citations (Scopus)

Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition

Gowrishankar, K., Snoyman, S., Pupo, G. M., Becker, T. M., Kefford, R. F. & Rizos, H., Jul 2012, In : Journal of Investigative Dermatology. 132, 7, p. 1850-1859 10 p.

Research output: Contribution to journalArticle

53 Citations (Scopus)

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

Liniker, E., Menzies, A. M., Kong, B. Y., Cooper, A., Ramanujam, S., Lo, S., Kefford, R. F., Fogarty, G. B., Guminski, A., Wang, T. W., Carlino, M. S., Hong, A. & Long, G. V., 1 Sep 2016, In : OncoImmunology. 5, 9, p. 1-7 7 p., e1214788.

Research output: Contribution to journalArticle

67 Citations (Scopus)

Acute radiation skin toxicity associated with BRAF inhibitors

Pulvirenti, T., Hong, A., Clements, A., Forstner, D., Suchowersky, A., Guminski, A., McNeil, C., Hersey, P., Fogarty, G., Kefford, R., Long, G. V. & Wang, W., 20 Jan 2016, In : Journal of Clinical Oncology. 34, 3, p. e17-e20 4 p.

Research output: Contribution to journalArticle

10 Citations (Scopus)

Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma

Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandal, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Robert, C., Mortier, L., Schachter, J., Schadendorf, D., Lesimple, T., Plummer, R., Ji, R., Zhang, P., Mookerjee, B., Legos, J. & 3 others, Kefford, R., Dummer, R. & Kirkwood, J. M., 9 Nov 2017, In : New England Journal of Medicine. 377, 19, p. 1813-1823 11 p.

Research output: Contribution to journalArticle

466 Citations (Scopus)

Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial

Dummer, R., Brase, J. C., Garrett, J., Campbell, C. D., Gasal, E., Squires, M., Gusenleitner, D., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Flaherty, K., Larkin, J., Robert, C., Kefford, R., Kirkwood, J. M., Hauschild, A., Schadendorf, D. & Long, G. V., 1 Mar 2020, In : The Lancet Oncology. 21, 3, p. 358-372 15 p.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial

Atkinson, V. G., Hauschild, A., Santinami, M., Mandala, M., Chiarion Sileni, V., Larkin, J., Nyakas, M. S., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Schadendorf, D., Feng, X., de Jong, E., Mookerjee, B., Kefford, R., Dummer, R., Kirkwood, J. M. & Long, G. V., 1 Oct 2018, In : Annals of Oncology. 29, Supplement 8, p. viii446 1 p., 1251P.

Research output: Contribution to journalMeeting abstract

Open Access

Analysis of the whole-exome sequencing of tumor and circulating tumor DNA in metastatic melanoma

Diefenbach, R. J., Lee, J. H., Strbenac, D., Yang, J. Y. H., Menzies, A. M., Carlino, M. S., Long, G. V., Spillane, A. J., Stretch, J. R., Saw, R. P. M., Thompson, J. F., Ch'ng, S., Scolyer, R. A., Kefford, R. F. & Rizos, H., 29 Nov 2019, In : Cancers. 11, 12, p. 1-14 14 p., 1905.

Research output: Contribution to journalArticle

Open Access
File
2 Downloads (Pure)

Annexin A1 expression in a pooled breast cancer series: Association with tumor subtypes and prognosis

Sobral-Leite, M., Wesseling, J., Smit, V. T. H. B. M., Nevanlinna, H., van Miltenburg, M. H., Sanders, J., Hofland, I., Blows, F. M., Coulson, P., Patrycja, G., Schellens, J. H. M., Fagerholm, R., Heikkilä, P., Aittomäki, K., Blomqvist, C., Provenzano, E., Ali, H. R., Figueroa, J., Sherman, M., Lissowska, J. & 193 others, Mannermaa, A., Kataja, V., Kosma, V. M., Hartikainen, J. M., Phillips, K. A., Couch, F. J., Olson, J. E., Vachon, C., Visscher, D., Brenner, H., Butterbach, K., Arndt, V., Holleczek, B., Hooning, M. J., Hollestelle, A., Martens, J. W. M., van Deurzen, C. H. M., van de Water, B., Broeks, A., Chang-Claude, J., Chenevix-Trench, G., Easton, D. F., Pharoah, P. D. P., García-Closas, M., de Graauw, M., Schmidt, M. K., Aghmesheh, M., Amor, D., Andrews, L., Antill, Y., Armitage, S., Arnold, L., Balleine, R., Bankier, A., Bastick, P., Beesley, J., Beilby, J., Bennett, B., Bennett, I., Berry, G., Blackburn, A., Bogwitz, M., Brennan, M., Brown, M., Buckley, M., Burgess, M., Burke, J., Butow, P., Byron, K., Callen, D., Campbell, I., Chauhan, D., Chauhan, M., Christian, A., Clarke, C., Colley, A., Cotton, D., Crook, A., Cui, J., Culling, B., Cummings, M., Dawson, S. J., deFazio, A., Delatycki, M., Dickson, R., Dixon, J., Dobrovic, A., Dudding, T., Edkins, T., Edwards, S., Eisenbruch, M., Farshid, G., Fawcett, S., Fellows, A., Fenton, G., Field, M., Firgaira, F., Flanagan, J., Fleming, J., Fong, P., Forbes, J., Fox, S., French, J., Friedlander, M., Gaff, C., Gardner, M., Gattas, M., George, P., Giles, G., Gill, G., Goldblatt, J., Greening, S., Grist, S., Haan, E., Hardie, K., Harris, M., Hart, S., Hayward, N., Healey, S., Heiniger, L., Hopper, J., Humphrey, E., Hunt, C., James, P., Jenkins, M., Jones, A., Kefford, R., Kidd, A., Kiely, B., Kirk, J., Koehler, J., Kollias, J., Kovalenko, S., Lakhani, S., Leaming, A., Leary, J., Lim, J., Lindeman, G., Lipton, L., Lobb, L., Mann, G., Marsh, D., McLachlan, S. A., Meiser, B., Meldrum, C., Milne, R., Mitchell, G., Newman, B., Niedermayr, E., Nightingale, S., O'Connell, S., O'Loughlin, I., Osborne, R., Pachter, N., Patterson, B., Peters, L., Phillips, K., Price, M., Purser, L., Reeve, T., Reeve, J., Richards, R., Rickard, E., Robinson, B., Rudzki, B., Saleh, M., Salisbury, E., Sambrook, J., Saunders, C., Saunus, J., Sayer, R., Scott, E., Scott, R., Scott, C., Seshadri, R., Sexton, A., Sharma, R., Shelling, A., Simpson, P., Southey, M., Spurdle, A., Suthers, G., Sykes, P., Tassell, M., Taylor, D., Taylor, J., Thierry, B., Thomas, S., Thompson, E., Thorne, H., Townshend, S., Trainer, A., Tran, L., Tucker, K., Tyler, J., Visvader, J., Walker, L., Walpole, I., Ward, R., Waring, P., Warner, B., Warren, G., Williams, R., Wilson, J., Winship, I., Wu, K., Young, M. A., Bowtell, D., Green, A., Webb, P., de Fazio, A., Gertig, D. & kConFab/AOCS Investigators, 2 Jul 2015, In : BMC Medicine. 13, p. 1-11 11 p., 156.

Research output: Contribution to journalArticle

Open Access
File
30 Citations (Scopus)
10 Downloads (Pure)

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

Shi, H., Hong, A., Kong, X., Koya, R. C., Song, C., Moriceau, G., Hugo, W., Yu, C. C., Ng, C., Chodon, T., Scolyer, R. A., Kefford, R. F., Ribas, A., Long, G. V. & Lo, R. S., Jan 2014, In : Cancer Discovery. 4, 1, p. 69-79 11 p.

Research output: Contribution to journalArticle

106 Citations (Scopus)

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma

Yokoyama, S., Woods, S. L., Boyle, G. M., Aoude, L. G., MacGregor, S., Zismann, V., Gartside, M., Cust, A. E., Haq, R., Harland, M., Taylor, J. C., Duffy, D. L., Holohan, K., Dutton-Regester, K., Palmer, J. M., Bonazzi, V., Stark, M. S., Symmons, J., Law, M. H., Schmidt, C. & 27 others, Lanagan, C., O'Connor, L., Holland, E. A., Schmid, H., Maskiell, J. A., Jetann, J., Ferguson, M., Jenkins, M. A., Kefford, R. F., Giles, G. G., Armstrong, B. K., Aitken, J. F., Hopper, J. L., Whiteman, D. C., Pharoah, P. D., Easton, D. F., Dunning, A. M., Newton-Bishop, J. A., Montgomery, G. W., Martin, N. G., Mann, G. J., Bishop, D. T., Tsao, H., Trent, J. M., Fisher, D. E., Hayward, N. K. & Brown, K. M., 1 Dec 2011, In : Nature. 480, 7375, p. 99-103 5 p.

Research output: Contribution to journalArticle

274 Citations (Scopus)

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W. J., Gangadhar, T. C., Patnaik, A., Dronca, R., Zarour, H., Joseph, R. W., Boasberg, P., Chmielowski, B., Mateus, C., Postow, M. A., Gergich, K., Elassaiss-Schaap, J. & 5 others, Li, X. N., Iannone, R., Ebbinghaus, S. W., Kang, S. P. & Daud, A., 20 Sep 2014, In : The Lancet. 384, 9948, p. 1109-1117 9 p.

Research output: Contribution to journalArticle

1142 Citations (Scopus)

Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma

Carlino, M. S., Gowrishankar, K., Saunders, C. A. B., Pupo, G. M., Snoyman, S., Zhang, X. D., Saw, R., Becker, T. M., Kefford, R. F., Long, G. V. & Rizos, H., Jul 2013, In : Molecular Cancer Therapeutics. 12, 7, p. 1332-1342 11 p.

Research output: Contribution to journalArticle

51 Citations (Scopus)

Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): correlation of tumor PD-L1 expression with outcome

Daud, A. I., Hamid, O., Ribas, A., Hodi, F. S., Hwu, W-J., Kefford, R., Wolchok, J., Hersey, P., Weber, J. S., Joseph, R., Gangadhar, T. C., Dronca, R. S., Patnaik, A., Zarour, H., Joshua, A. M., Gergich, K., Wu, D., Lunceford, J. K., Emancipator, K., Dolled-Filhart, M. & 4 others, Li, N., Ebbinghaus, S., Kang, S. P. & Robert, C., 30 Sep 2014, In : Cancer Research. 74, 19, 1 p., CT104.

Research output: Contribution to journalMeeting abstract

A phase III trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in chemotherapy-naive patients with metastatic melanoma: analysis by age

Kefford, R., Hersh, E., Del Vecchio, M., Brown, M. P., Loquai, C., Testori, A., Robert, C., Li, M., Elias, Renschler, M. F. & Hauschild, A., Jul 2013, In : JDDG - Journal of the German Society of Dermatology. 11, Supplement 7, p. 55-56 2 p., P-100.

Research output: Contribution to journalMeeting abstract

A phase III trial of nab-paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: A subanalysis based on BRAF status

Hersh, E., Del Vecchio, M., Brown, M. P., Kefford, R., Loquai, C., Testori, A., Robert, C., Li, M., Elias, I., Renschler, M. F. & Hauschild, A., 20 May 2013, In : Journal of Clinical Oncology. 31, 15 supplement, p. 9030-9030 1 p.

Research output: Contribution to journalMeeting abstract

A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma

O'Day, S., Gonzalez, R., Kim, K., Chmielowski, B., Kefford, R., Long, G., Loquai, C., Cowey, C. L., Hauschild, A., Hainsworth, J. D., Hersey, P., Boyle, F., Evans, T. R. J., Hamid, O., Meneses, N., Andresen, C., Ren, M., O'Brien, J. P. & Flaherty, K., 20 May 2013, In : Journal of Clinical Oncology. 31, 15, p. 9026-9026 1 p.

Research output: Contribution to journalMeeting abstract

A pooled analysis of 655 patients with advanced melanoma enrolled in KEYNOTE-001: long-term efficacy of pembrolizumab (MK-3475)

Daud, A., Joshua, A. M., Ribas, A., Robert, C., Hodi, F. S., Wolchok, J., Hwu, W-J., Weber, J. S., Gangadhar, T. C., Joseph, R., Dronca, R., Patnaik, A., Zarour, H., Kefford, R., Lindia, J., Li, X. N., Ebbinghaus, S., Kang, S. P. & Hamid, O., Aug 2015, In : Asia-Pacific Journal of Clinical Oncology. 11, p. 43-43 1 p.

Research output: Contribution to journalMeeting abstract

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma

Hersh, E. M., Del Vecchio, M., Brown, M. P., Kefford, R., Loquai, C., Testori, A., Bhatia, S., Gutzmer, R., Conry, R., Haydon, A., Robert, C., Ernst, S., Homsi, J., Grob, J. J., Kendra, K., Agarwala, S. S., Li, M., Clawson, A., Brachmann, C., Karnoub, M. & 3 others, Elias, I., Renschler, M. F. & Hauschild, A., 1 Nov 2015, In : Annals of Oncology. 26, 11, p. 2267-2274 8 p., mdv324.

Research output: Contribution to journalArticle

31 Citations (Scopus)

Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma

Chan, M. M. K., Kefford, R. F., Carlino, M., Clements, A. & Manolios, N., 14 Jan 2015, In : Journal of Immunotherapy. 38, 1, p. 37-39 3 p.

Research output: Contribution to journalArticle

82 Citations (Scopus)

Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies

Cust, A. E., Drummond, M., Kanetsky, P. A., Australian Melanoma Family Study Investigators, Leeds Case-Control Study Investigators, Goldstein, A. M., Barrett, J. H., MacGregor, S., Law, M. H., Iles, M. M., Bui, M., Hopper, J. L., Brossard, M., Demenais, F., Taylor, J. C., Hoggart, C., Brown, K. M., Landi, M. T., Newton-Bishop, J. A., Mann, G. J. & 1 others, Bishop, D. T., Dec 2018, In : Journal of Investigative Dermatology. 138, 12, p. 2617-2624 8 p.

Research output: Contribution to journalArticle

Open Access
File
13 Citations (Scopus)
9 Downloads (Pure)

Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies

Lee, J. H., Long, G. V., Menzies, A. M., Lo, S., Guminski, A., Whitbourne, K., Peranec, M., Scolyer, R., Kefford, R. F., Rizos, H. & Carlino, M. S., 1 May 2018, In : JAMA Oncology. 4, 5, p. 717-721 5 p.

Research output: Contribution to journalArticle

59 Citations (Scopus)

Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001

Robert, C., Joshua, A. M., Kefford, R., Joseph, R. W., Wolchok, J. D., Hodi, F. S., Hamid, O., Weber, J. S., Gangadhar, T. C., Dronca, R. S., Patnaik, A., Zarour, H. M., Hwu, W-J., Hersey, P., Daud, A., Giannotti, M., Li, X. N., Ebbinghaus, S., Kang, S. P. & Ribas, A., 20 May 2015, In : Journal of Clinical Oncology. 33, 15 supplement, p. 9050 1 p.

Research output: Contribution to journalMeeting abstract

Association of pembrolizumab with tumor response and survival among patients with advanced melanoma

Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W. J., Weber, J. S., Gangadhar, T. C., Hersey, P., Dronca, R., Joseph, R. W., Zarour, H., Chmielowski, B., Lawrence, D. P., Algazi, A., Rizvi, N. A., Hoffner, B. & 8 others, Mateus, C., Gergich, K., Lindia, J. A., Giannotti, M., Li, X. N., Ebbinghaus, S., Kang, S. P. & Robert, C., 19 Apr 2016, In : JAMA: Journal of the American Medical Association. 315, 15, p. 1600-1609 10 p.

Research output: Contribution to journalArticle

487 Citations (Scopus)

Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature

Ribas, A., Robert, C., Hodi, F. S., Wolchok, J. D., Joshua, A. M., Hwu, W-J., Weber, J. S., Zarour, H. M., Kefford, R., Loboda, A., Albright, A., Kang, S. P., Ebbinghaus, S., Yearley, J., Murphy, E., Nebozhyn, M., Lunceford, J. K., McClanahan, T., Ayers, M. & Daud, A., 20 May 2015, In : Journal of Clinical Oncology. 33, 15 supplement, p. 3001 1 p.

Research output: Contribution to journalMeeting abstract

Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure

Cust, A. E., Drummond, M., Bishop, D. T., Azizi, L., Schmid, H., Jenkins, M. A., Hopper, J. L., Armstrong, B. K., Aitken, J. F., Kefford, R. F., Giles, G. G., Demenais, F., Goldstein, A. M., Barrett, J. H., Kanetsky, P. A., Elder, D. E., Mann, G. J. & Newton-Bishop, J. A., Oct 2019, In : Journal of the European Academy of Dermatology and Venereology. 33, 10, p. 1874-1885 12 p.

Research output: Contribution to journalArticle

Open Access
File
1 Citation (Scopus)
3 Downloads (Pure)

Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001

Wolchok, J. D., Hamid, O., Ribas, A., Robert, C., Kefford, R., Hwu, W-J., Weber, J. S., Joshua, A. M., Gangadhar, T. C., Dronca, R. S., Daud, A., Patnaik, A., Joseph, R. W., Zarour, H. M., Li, X. N., Xue, D., Ebbinghaus, S., Kang, S. P., Perrone, A. M. & Hodi, F. S., 20 May 2015, In : Journal of Clinical Oncology. 33, 15 supplement, p. 3000 1 p.

Research output: Contribution to journalMeeting abstract

Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma

Kong, B. Y., Micklethwaite, K. P., Swaminathan, S., Kefford, R. F. & Carlino, M. S., Apr 2016, In : Melanoma Research. 26, 2, p. 202-204 3 p.

Research output: Contribution to journalArticle

50 Citations (Scopus)

Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475

Joseph, R. W., Elassaiss-Schaap, J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, M., Robert, C., Daud, A., Hwu, W-J., Kefford, R., Hersey, P., Weber, J. S., Patnaik, A., De Alwis, D. P., Perrone, A. M., Kang, S. P., Ebbinghaus, S., Anderson, K. M. & Gangadhar, T. C., 20 May 2014, In : Journal of Clinical Oncology. 32, 15, p. 3015 1 p.

Research output: Contribution to journalMeeting abstract

Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab

Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W. J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Dronca, R., Hersey, P., Weber, J. S., Patnaik, A., de Alwis, D. P., Perrone, A., Zhang, J., Kang, S. P., Ebbinghaus, S. & 2 others, Anderson, K. M. & Gangadhar, T. C., 15 Oct 2018, In : Clinical cancer research : an official journal of the American Association for Cancer Research. 24, 20, p. 4960-4967 8 p.

Research output: Contribution to journalArticle

62 Citations (Scopus)

bcGST: an interactive bias-correction method to identify over-represented gene-sets in boutique arrays

Wang, K. Y. X., Menzies, A. M., Silva, I. P., Wilmott, J. S., Yan, Y., Wongchenko, M., Kefford, R. F., Scolyer, R. A., Long, G. V., Tarr, G., Mueller, S. & Yang, J. Y. H., 15 Apr 2019, In : Bioinformatics. 35, 8, p. 1350-1357 8 p.

Research output: Contribution to journalArticle

1 Citation (Scopus)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma

Wilmott, J. S., Menzies, A. M., Haydu, L. E., Capper, D., Preusser, M., Zhang, Y. E., Thompson, J. F., Kefford, R. F., Von Deimling, A., Scolyer, R. A. & Long, G. V., 5 Mar 2013, In : British Journal of Cancer. 108, 4, p. 924-931 8 p.

Research output: Contribution to journalArticle

49 Citations (Scopus)

BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)

Sosman, J. A., Daud, A., Weber, J. S., Kim, K., Kefford, R., Flaherty, K., Infante, J. R., Hamid, O., Cebon, J. S., Schuchter, L. M., McWilliams, R. R., Sznol, M., Sharfman, W. H., Algazi, A. P., Lewis, K. D., Little, S. M., Sun, P., Long, G., Patel, K. & Gonzalez, R., 20 May 2013, In : Journal of Clinical Oncology. 31, 15 supplement, p. 9005-9005 1 p.

Research output: Contribution to journalMeeting abstract

BRAF inhibitor acquired resistance: a multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms.

Johnson, D. B., Menzies, A. M., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Sucker, A., Rizos, H., Hugo, W., Gutzmer, R., Kefford, R., Gogas, H., Kong, X., Scolyer, R. A., Garraway, L. A., Sosman, J. A., Ribas, A., Lo, R., Long, G. V. & Schadendorf, D., 20 May 2015, In : Journal of Clinical Oncology. 33, 15 supplement, p. 9008-9008 1 p.

Research output: Contribution to journalMeeting abstract

BRAF inhibitor activity in V600R metastatic melanoma

Klein, O., Clements, A., Menzies, A. M., O'Toole, S., Kefford, R. F. & Long, G. V., Mar 2013, In : European Journal of Cancer. 49, 5, p. 1073-1079 7 p.

Research output: Contribution to journalArticle

79 Citations (Scopus)

BRAF inhibitor activity in V600R metastatic melanoma-Response

Klein, O., Clements, A., Menzies, A. M., O'Toole, S., Kefford, R. F. & Long, G. V., May 2013, In : European Journal of Cancer. 49, 7, p. 1797-1798 2 p.

Research output: Contribution to journalLetter

13 Citations (Scopus)

BRAF inhibitor resistance mechanisms in metastatic melanoma: Spectrum and clinical impact

Rizos, H., Menzies, A. M., Pupo, G. M., Carlino, M. S., Fung, C., Hyman, J., Haydu, L. E., Mijatov, B., Becker, T. M., Boyd, S. C., Howle, J., Saw, R., Thompson, J. F., Kefford, R. F., Scolyer, R. A. & Long, G. V., 1 Apr 2014, In : Clinical Cancer Research. 20, 7, p. 1965-1977 13 p.

Research output: Contribution to journalArticle

260 Citations (Scopus)

BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma

Mann, G. J., Pupo, G. M., Campain, A. E., Carter, C. D., Schramm, S. J., Pianova, S., Gerega, S. K., De Silva, C., Lai, K., Wilmott, J. S., Synnott, M., Hersey, P., Kefford, R. F., Thompson, J. F., Yang, Y. H. & Scolyer, R. A., Feb 2013, In : Journal of Investigative Dermatology. 133, 2, p. 509-517 9 p.

Research output: Contribution to journalArticle

116 Citations (Scopus)

BRAF mutation by age-decade and body mass index in metastatic melanoma

Menzies, A. M., Visintin, L., Chatfield, M. D., Carlino, M. S., Howle, J. R., Scolyer, R. A., Thompson, J. F., Kefford, R. F. & Long, G. V., 20 May 2011, In : Journal of Clinical Oncology. 29, 15, p. 8507-8507 1 p.

Research output: Contribution to journalMeeting abstract

Break-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets)

Kirkwood, J. M., Long, G. V., Trefzer, U., Davies, M. A., Ascierto, P. A., Chapman, P. B., Puzanov, I., Hauschild, A., Robert, C., Kefford, R., Goodman, V. L., Switzky, J. C., Swann, R. S., Martin, A-M., Guckert, M. E., Streit, M. R. W. & Schadendorf, D., 20 May 2012, In : Journal of Clinical Oncology. 30, Supplement 15, p. 8501-8501 1 p.

Research output: Contribution to journalMeeting abstract

BRIM-2: an open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma

Ribas, A., Kim, K. B., Schuchter, L. M., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Flaherty, K. T., Moschos, S. J., Lawrence, D. P., Hersey, P., Kefford, R. F., Chmielowski, B., Puzanov, I., Li, J., Nolop, K. B., Lee, R. J., Joe, A. K. & Sosman, J. A., 20 May 2011, In : Journal of Clinical Oncology. 29, 15, p. 8509 1 p., 8509.

Research output: Contribution to journalMeeting abstract

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: A case series

Carlino, M. S., Vanella, V., Girgis, C., Giannarelli, D., Guminski, A., Festino, L., Kefford, R. F., Menzies, A. M., Long, G. V. & Ascierto, P. A., 22 Nov 2016, In : British Journal of Cancer. 115, 11, p. 1280-1284 5 p.

Research output: Contribution to journalArticle

13 Citations (Scopus)

Characteristics of pyrexia in BRAF(V600E/K) metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial

Menzies, A. M., Ashworth, M. T., Swann, S., Kefford, R. F., Flaherty, K., Weber, J., Infante, J. R., Kim, K. B., Gonzalez, R., Hamid, O., Schuchter, L., Cebon, J., Sosman, J. A., Little, S., Sun, P., Aktan, G., Ouellet, D., Jin, F., Long, G. V. & Daud, A., 1 Feb 2015, In : Annals of Oncology. 26, 2, p. 415-421 7 p., mdu529.

Research output: Contribution to journalArticle

51 Citations (Scopus)

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1 based immunotherapy

Lim, S. Y., Lee, J. H., Nur Gide, T., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., Scolyer, R. A., Long, G. V. & Rizos, H., Mar 2019, In : Clinical Cancer Research. 25, 5, p. 1557-1563 7 p.

Research output: Contribution to journalArticle

28 Citations (Scopus)